Abstract: Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.

Abstract: An antibody binding to CCR5 and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is 65% or lower has improved properties in anti-inflammatory therapy.

Abstract: The present invention discloses a combination sampling and pressure relief valve. In particular embodiments, the valve includes a main body having a central bore therethrough, the central bore having first and second chamfered surfaces; a front surface having an aperture in communication with the central bore; and a rear surface having an aperture in communication with the central bore; a valve seat/stem assembly located within the central bore, the valve seat/stem assembly having first and second chamfered surfaces that are complementary to the main bore chamfered surfaces; a spring extending between the valve seat/stem assembly and a rear end cap of the valve; and, a drain aperture extending perpendicularly from the central bore to ambient, the drain aperture located between the central bore first and second chamfered surfaces. Other embodiments of the valve are disclosed.

Abstract: An antibody binding to CCR5 characterized in that the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 1, and has advantageous properties for the treatment of immunosuppressive diseases.

Abstract: The invention relates to a packaging machine for packing food products in a plastic packaging, said machine comprising a device for applying a transponder to the plastic packaging, and a system for data exchange between the transponder and a computer unit and/or a regulating unit, by which means data can be transmitted to the transponder or called therefrom.

Abstract: The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.

Abstract: A grounding device for a roll-out electrical component is provided. The grounding device includes an actuation assembly, a static grounding contact assembly, and a biasing device. The actuation assembly structured to be engaged/disengaged by a roll-out electrical component. The static grounding contact assembly has at least one static grounding contact member that is structured to move between a first position, wherein the static grounding contact member does not contact a roll-out electrical component at least one contact, and a second position, wherein the static grounding contact member contacts, and is in electrical communication with, the roll-out electrical component at least one contact. The static grounding contact assembly is coupled to the actuation assembly and responsive to the position of the roll-out electrical component. The biasing device is structured to bias the actuation assembly and the static grounding contact member to their respective first positions.

Abstract: The present invention provides a conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 molecules in the composition. Also provided is a composition in which the monoPEGylated conjugates comprise conjugates in which the PEG groups are attached to groups randomly selected from the lysine side chains of NK4 molecules and the N-terminal amino groups of NK4 molecules. A method for the treatment of cancer by administering 1 to 30 mg monoPEGylated NK4 per kg per day is further provided.

Abstract: A grounding device for a roll-out electrical component is provided. The grounding device includes an actuation assembly, a static grounding contact assembly, and a biasing device. The actuation assembly structured to be engaged/disengaged by a roll-out electrical component. The static grounding contact assembly has at least one static grounding contact member that is structured to move between a first position, wherein the static grounding contact member does not contact a roll-out electrical component at least one contact, and a second position, wherein the static grounding contact member contacts, and is in electrical communication with, the roll-out electrical component at least one contact. The static grounding contact assembly is coupled to the actuation assembly and responsive to the position of the roll-out electrical component. The biasing device is structured to bias the actuation assembly and the static grounding contact member to their respective first positions.

Abstract: The present invention provides an Al—Zn—Mg—Cu casting alloy that provides high strength for automotive and aerospace applications and optimized stress corrosion cracking resistance in highly corrosive and tensile environments. The inventive alloy composition includes about 3.5 wt. % to about 5.5 wt. % Zn; about 1.0 wt. % to about 3.0 wt. % Mg; about 0.5 wt. % to about 1.2 wt. % Cu; less than about 1.0 wt. % Si; less than about 0.30 wt. % Mn; less than about 0.30 wt. % Fe; and a balance of Al and incidental impurities.

Abstract: The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.

Abstract: A process for selecting human cells for the production of human proteins by endogenous gene activation allows human proteins to be produced in economically feasible quantities and in a form suitable for producing a pharmaceutical composition. Also disclosed is a process for producing human proteins in a cell line identified in this matter.

Abstract: The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.

Abstract: Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.

Abstract: This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula I: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, n, y, and Ar is as defined and described herein. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula I.

Abstract: This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I): where R1 is H, alkyl or phenylalkyl; R2 is H, alkyl, alkenyl or phenylalkyl; or R1 and R2 taken together as Z are —CH2C—H2—, —CH2C(R6)(R7)CH2— or —CH2C(R8)(R9)—C(R10)(R11)CH2—, where R6, R8 and R10 are, independently, H, alkyl or hydroxyl and R7, R9 and R11 are, independently, H or alkyl; A is alkylene or alkenylene; X is CO2R3, P(O)(OR4)(OR5), 3,5-dioxo-1,2,4-oxadiazolidin-2-yl or 5-tetrazolyl in which R3, R4 and R5 are, independently, H or alkyl, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula (I).

Abstract: An interface linkage assembly for a network protector is provided. The network protector includes a circuit breaker structured to move in and out of a housing assembly, and having a mechanical trip assembly and an electrical close assembly. The interface linkage includes a coupling device, a housing assembly portion and a rollout portion. The coupling device has a first component and a second component. The housing assembly portion is coupled to the coupling device first component. The rollout portion is coupled to the coupling device second component. The rollout portion is structured to be coupled to the mechanical trip assembly and the electrical close assembly, and further structured to move the mechanical trip assembly over a lesser arc and the electrical close assembly over a greater arc.

Abstract: A heat treatable aluminum alloy for shaped castings includes from about 3.5-5.5% Zn, from about 1-1.5% Mg, less than about 1% Si, less than about 0.30% Mn, and less than about 0.3% Fe and other incidental impurities.

Abstract: A heat treatable aluminum alloy for shaped castings includes from about 3.5-5.5% Zn, from about 1-3% Mg, about 0.05-0.5% Cu, and less than about 1% Si.

Abstract: A handle assembly for a network protector where the network protector includes a circuit breaker and a housing assembly, the circuit breaker having a trip bar structured to move between a first position and a second position corresponding to an open and closed position of the circuit breaker, respectively, the housing assembly having a sidewall with an opening. The handle assembly includes a linkage assembly, a shaft assembly, a handle member and locking assembly. The shaft assembly has a shaft, where the shaft rotatably is disposed in the opening and structured to move between a first and second position. The handle member has an elongated body and an elongated grip extending generally perpendicular to the handle body. The handle body is coupled to, and structured to rotate, the shaft. The locking assembly has an elongated release grip.